Chronic News and Research

RSS

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

The combination of tenofovir disoproxil fumarate and entecavir induces a high rate of viral suppression in patients with chronic hepatitis B virus infection who have failed multiple nucleos(t)ide analogue regimens, phase IIIb results indicate.

13 Apr 2016

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review.

13 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Minimally important dyspnoea, fatigue changes in PAH patients defined

Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension.

13 Apr 2016

Coronary heart disease, cancer less likely among people with learning disabilities

Coronary heart disease and cancer rates among people with learning disabilities are nearly a third lower than the general population, says new research.

13 Apr 2016

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy.

13 Apr 2016

Study finds link between low pollution levels and stronger lungs in California kids

A USC study that tracked Southern California children over a 20-year period has found they now have significantly fewer respiratory symptoms as a result of improved air quality.

13 Apr 2016

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease.

13 Apr 2016

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2).

13 Apr 2016

Combination of sugar and polyphenols may prevent occurrence of neurodegenerative disease

Catherine Aaron and Gabrielle Beaudry were 17 when they knocked on the door of the laboratory of Alex Parker, a neuroscience researcher at the University of Montreal Hospital Research Centre. While students at Collège Jean-de-Brébeuf in Montreal, they were looking for a mentor for an after-school research project. Two and half years later, the results of this scientific adventure were published today in the Journal of Agricultural and Food Chemistry.

13 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

13 Apr 2016

New research shows type 2 diabetes as important risk factor for chronic liver disease

People with type 2 diabetes are at greater risk of serious liver disease than those without the condition, new research has shown.

13 Apr 2016

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

13 Apr 2016

Inserm study reveals potential of secondary system to improve heart function

Heart failure affects over one million people in France. Although the blood system is the first to have been explored for the purpose of improving heart function, a study by Inserm has revealed the potential of a secondary system that had previously received scant attention.

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers at Penn State College of Medicine.

12 Apr 2016

PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide.

12 Apr 2016

New plant-derived oral drug can prevent progression of multiple sclerosis

An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS).

12 Apr 2016

Chronic News and Research

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

Dynamic HBsAg measurements predict HBV inactivity

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Minimally important dyspnoea, fatigue changes in PAH patients defined

Coronary heart disease, cancer less likely among people with learning disabilities

Hepatitis C treatment can be provided safely, effectively within community-based setting

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Study finds link between low pollution levels and stronger lungs in California kids

Scientists reveal mechanism involved in regulation of lymphangiogenesis

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

Combination of sugar and polyphenols may prevent occurrence of neurodegenerative disease

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

New research shows type 2 diabetes as important risk factor for chronic liver disease

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

Inserm study reveals potential of secondary system to improve heart function

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

New plant-derived oral drug can prevent progression of multiple sclerosis

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Latest News